Search results
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 5 hours agoKey Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal Cancer Patients Fully Enrolled NUC-7738 plus Pembrolizumab Demonstrated Encouraging Anti-Cancer Activity in Several Patients
Precigen Reports First Quarter 2024 Financial Results and Business Updates
WRBL Columbus· 2 days ago– Pivotal Phase 2 study data of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis to be presented at the 2024 ASCO Annual Meeting as a late-breaking oral presentation ...
Earnings call: AIM ImmunoTech highlights Q1 2024 progress on cancer trials
Investing.com· 21 hours agoAIM ImmunoTech (NYSE: AIM ) Inc. (NYSE American: AIM) provided an optimistic update during its first...
Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma...
Benzinga via Yahoo Finance· 3 days agoMonday, Merck & Co Inc (NYSE:MRK) announced the discontinuation of the vibostolimab and ...
Merck cancels trial of melanoma treatment due to immune-mediated adverse events
Clinical Trials Arena via Yahoo Finance· 3 days agoUS pharmaceutical company Merck & Co Inc (MSD) has discontinued a Phase III trial investigating a...
Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch
InvestorPlace· 7 hours agoPenny stocks to buy understandably offer many enticing attributes, not least of which is the...
Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting
WPRI Providence· 4 days agoAstellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will share new research from across its innovative portfolio of approved and investigational cancer therapies during ...
Therapeutic opportunities for hypermutated urothelial carcinomas beyond immunotherapy
Medical Xpress· 3 days agoIn an editorial, in Oncoscience titled "Therapeutic opportunities for hypermutated urothelial...
Third Party Withdraws Appeal Related to Cantargia Patent
Digital Journal· 8 hours agoNadunolimab is also investigated with chemotherapy in the clinical trials CAPAFOUR, NCT04990037 , and CESTAFOUR, NCT05116891 , and with the checkpoint inhibitor pembrolizumab
People Spent the Most Money on These 25 Prescription Drugs Last Year
Healthline via AOL· 14 hours agoA new study found that spending on prescription drugs in the U.S. has skyrocketed in the last year....
